Impact of ceftriaxone de-restriction on the occurrence of ESBL-positive bacterial strains and antibiotic consumption

Journal of Chemotherapy

Volumn 23, Issue 6, 2011, Pages 341-344

  Skrlin, J ^a   Bacic Vrca, V ^a,b   Marusic, S ^a   Ciric Crncec, M ^a   Mayer, L ^c  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Antibiotic policy; Antibiotic use; Ceftriaxone; Cephalosporins; ESBLs; Resistance

Indexed keywords

CARBAPENEM; CEFTRIAXONE; CEFUROXIME; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLONE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; DRUG USE; HUMAN; INTERVENTION STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; BACTERIUM; BIOSYNTHESIS; DRUG EFFECT; DRUG UTILIZATION; ENZYMOLOGY; STATISTICS;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; CEFTRIAXONE; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; HUMANS;

EID: 84864924285     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.6.341     Document Type: Article

References (25)

1. I World Health Organisation: WHO global strategy for containment of antimicrobial resistance. World Health Organisation, Manila 2005.
2. Foster KR, Grundmann H. Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Med 2006; 3: 177-80.
3. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 2006· 42· 153-63
4. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
5. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
6. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrumβ-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol2001; 39: 2206-12.
7. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum ~-lactamases. Clin Infect Dis 2004; 39: 31-7.
8. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33: 1288-94.
9. Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: Changing epidemiology and drug treatment choices. Drugs 2010; 70: 313-33.
10. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase- producing organisms. J Hosp Infect 2009; 73: 345-54.
11. Urbanek K, Kolar M, Loveckova Y, Strojil J, Santava L. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Ther 2007; 32: 403-8.
12. WHO Collaborating Centre for Drug Statistics Methodology. Anatomic Therapeutic Chemical (ATC) Classification Index with Defined Daily Doses (ODDs). Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2005.
13. Isenberg HD. Clinical microbiology procedures handbook. American society for Microbiology, Washington, D.C., 2004.
14. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing-Nineteenth Informational Supplement: Approved Standard M100-S19. CLSI, Wayne, PA,USA, 2009.
15. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing-Nineteenth Informational Supplement: Approved Standard M100-S15. CLSI, Wayne, PA,USA, 2005.
16. Thomson KS, Sanders CC. Detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother 1992; 36: 1877-82.
17. Jiang X, Zhang Z, Li M, Zhou Z, Ruan F, Lu Y. detection of extendedspectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:2990-5.
18. Tambic Andrasevic A, Tambic T, Kalenic S et al. (2009) Antibiotic resistance in Croatia, 2009. Zagreb: The Croatian Academy of Medical Sciences. Available at: http://iskra.bfm.hr/upload/AMZH_lzvjesce_2009.pdf (accessed 22 June 2011).
19. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. lnt J Antimicrob Agents, 2001; 17: 357-63.
20. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-8.
21. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 30: 1233-7.
22. Urbanek K, Kolar M, Loveckova Y, Strojil J, Santava L. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Ther 2007; 32: 403-8.
23. Kim JY, Sohn JW, Park OW, Yoon YK, Kim YM, Kim MJ. Control of extended-spectrum (beta}-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 2008; 62: 416-21.
24. Schoevaerdts D, Bogaerts P, Grimmelprez A, de Saint-Hubert M, Delaere B, Jamart J, et al. Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital. BMC Infect Dis 2011; 11: 12.
25. Wu UI, Yang CS, Chen WC, Chen YC, Chang SC. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. J Microbiol Immunol Infect 2010; 43: 310-6.